DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for bone neoplasm — screening already-approved drugs against its 18-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleBone neoplasm maps to a 18-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for bone neoplasm is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
ral guanine nucleotide dissociation stimulator (RALGDS) — RALGDS is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet unxdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 3KH0 · 2.1 Å · ligand UNKNOWN ATOM OR ION (UNX). Experimental structure, not a prediction.
What the evidence adds up to
The abstracts span nearly a century and show a consistent theme: treatment of bone neoplasms has long been limited, and the evidence for any single effective therapy is thin. A 1925 report on radiation treatment describes only three early cases, two probably benign and one a spindle-cell sarcoma later reclassified as giant-cell sarcoma; the authors explicitly state they are not outlining a treatment regimen, and the other cases in the series had been observed for less than a year. A 1949 textbook review reflects the era's reliance on radical surgery, with radiation and hope as adjuncts. By 1985, the emphasis had shifted to multimodal treatment, with chemotherapy reported to have its greatest impact on osteosarcoma, Ewing's sarcoma, and malignant fibrous histiocytoma of bone, though the abstract provides no response rates or survival figures.
More recent reviews from 2011 and 2014 describe the molecular mechanisms of tumour-induced bone disease, noting a vicious cycle of bone destruction and tumour progression, but they offer no clinical efficacy data. The 2011 review discusses emerging targeted therapies for bone disease in solid tumours and multiple myeloma, while the 2014 paper states plainly that treatment of bone metastases is quite limited and the effect is not significant. A 2024 review on bone matrix-forming tumours highlights the discovery of driver genetic alterations and their protein products as potential targets for diagnosis and therapy, but again provides no patient outcomes. The 2025 reviews repeat the same assessment: bone cancer remains challenging, with high risk of recurrence and metastasis, and current treatments have limitations.
No abstract in this set reports a successful clinical trial, a survival benefit, or a response rate for any drug in bone neoplasms. The historical record shows a shift from amputation to radiation to chemotherapy to molecular targeting, but the evidence base for efficacy remains largely descriptive or preclinical. What is still missing is prospective clinical data: randomised trials with adequate sample sizes, long-term follow-up, and patient stratification by tumour type and genetic alteration. Without that, the promise of targeted therapies remains unproven.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Current Medicinal Chemistry · 2011 · 10 citations
Pathophysiology and Pharmacological Targeting of Tumor-Induced Bone Disease: Current Status and Emerging Therapeutic Interventions
AbstractBone disease is a common complication of metastatic solid tumors but also of primary hematological malignancies such as multiple myeloma. Our understanding of the molecular mechanisms underlying the development of bone disease by solid tumors and multiple myeloma has been significantly improved. A complex inter-dependence exists between bone disease and malignant cell growth, creating a vicious cycle of extensive bone destruction and tumor progression. Although myeloma and solid tumors share a number of common molecular pathogenetic mechanisms, they involve distinct pathophysiological pathways, resulting in osteoclastic bone resorption and inhibition of bone formation. In this review, we analyze the molecular mechanisms, involved in tumor-induced bone disease and discuss the current therapeutic approaches and the most recent clinical developments of emerging targeted therapies.
Neoplasms of Bone and Related Conditions. Their Etiology, Pathogenesis, Diagnosis, and Treatment. By Bradley L. Coley, M.D., Attending Surgeon, Bone Tumor Department, Memorial Hospital for Cancer and Allied Diseases; Assistant Professor of Clinical Surgery, Cornell. 67/8 × 10 in. Pp. 765 + xiv, with 389 illustrations. 1949. New York: Paul B. Hoeber Inc. $17.50
AbstractJournal Article Neoplasms of Bone and Related Conditions. Their Etiology, Pathogenesis, Diagnosis, and Treatment. By Bradley L. Coley, M.D., Attending Surgeon, Bone Tumor Department, Memorial Hospital for Cancer and Allied Diseases; Assistant Professor of Clinical Surgery, Cornell. 67/8 × 10 in. Pp. 765 + xiv, with 389 illustrations. 1949. New York: Paul B. Hoeber Inc. $17.50 Get access Neoplasms of Bone and Related Conditions. Their Etiology, Pathogenesis, Diagnosis, and Treatment. By Bradley LColey, M.D., Attending Surgeon, Bone Tumor Department, Memorial Hospital for Cancer and Allied Diseases; Assistant Professor of Clinical Surgery, Cornell. 67/8 × 10 in. Pp. 765 + xiv, with 389 illustrations. 1949. New York: Paul B. Hoeber Inc. $17.50. British Journal of Surgery, Volume 37, Issue 145, July 1949, Pages 125–126, https://doi.org/10.1002/bjs.18003714542 Published: 05 December 2005
Microenvironment and therapeutic targets of metastatic bone cancer
AbstractCurrently,the treatment of bone metastases is quite limited,and the effect is not significant.It is a tempting but difficult task to find valid therapy.The recent research on bone microenvironment,including the osteoblasts,osteoclasts and tumor cells et al,may provide new targets and methods for the treatment of bone metastases.
Key words:
Neoplasm metastasis; Bone tissue ; Targeted therapy
AbstractTHE question of the proper treatment of bone tumors is one which has long been under consideration and one in which there has been considerable difference of opinion. Until quite recently, practically the only treatment considered was surgery and this usually meant radical amputation of the involved part. However, there has been a tendency to the less radical surgical treatment, especially of the benign bone tumors, since Bloodgood pointed out that many could be cured by simple curettage. Even in malignant cases, the field of surgery is very limited, as metastasis has usually occurred or cannot be prevented by the time the case is first seen. With the increasing advance in the science of radiation therapy in the treatment of all types of neoplasms, more attempts are being made to successfully treat bone tumors by radiation. The increasing reports of cases in the literature, especially the recent work of Herendeen (1) and of Palmer (2), show that advance is being made. The purpose of this paper is not to outline any régime of treatment for bone tumors but merely to give a preliminary report and analysis of three of the earlier cases of a series which have been under radiation treatment with definite benefit. The other cases of the series have been under observation less than one year and will not be described at this time. Of the three cases we will report, the first two were probably benign, although biopsy was not done. The third case was reported spindle-cell sarcoma at the time biopsy was taken, but later giant-cell sarcoma. The boy is twelve years of age, an unusual age for giant-cell tumor, the youngest patient in Meyerding's (3) series of cases being sixteen years of age. This, together with the history and the X-ray evidence in this case, points more to periosteal sarcoma than to giant-cell tumor. The first two cases were treated with copper filtered high voltage X-ray, while the third case was treated with moderate voltage aluminum filtered X-ray and buried lightly filtered radium. In the treatment of bone tumors of the extremities, the method advised by Juengling is to be recommended. He uses square aluminum boxes which surround the involved area and are filled with fuller's earth or an organic preparation, as radioplastin. This method insures a more homogeneous radiation to all parts by utilizing the scattered radiation. Also, four exact portals of entry may be used. Case No. 1.—Female, age 12, reported for treatment December 5, 1922. Chief complaint: Pain and swelling of anterior surface of upper part of left tibia. Past medical history: Measles and mumps in childhood, otherwise always well and healthy. Family history: Father and mother living and well. No history of tuberculosis or malignancy in family. History of present illness: About three years previous to examination the patient had quite a severe fall, striking the left shin and causing considerable skin abrasion.
AbstractHistorically, treatment for all forms of cancer has been radical surgical excision, possibly followed by radiation and hope, and in the last event, by chemotherapy. Early referral to a comprehensive cancer treatment center provides the patient with the best hope of cure. This article will provide information on the therapy of the malignant primary bone tumors most frequently seen at The University of Texas, M.D. Anderson Hospital and Tumor Institute at Houston. Emphasis is on the multimodal treatment of the three tumors on which chemotherapy is having its greatest impact: osteosarcoma, Ewing 's sarcoma, and malignant fibrous histiocytoma (MFH) of bone.
Advances in Anatomic Pathology · 2024 · 0 citations
Bone Matrix-forming Tumors
AbstractBone matrix-forming tumors are a group of neoplasms that exhibit differentiation toward any stage of osteoblast development. Their clinicopathologic features can resemble one another, yet their clinical management may vary significantly. Therefore, appropriate treatment requires accurate diagnosis, which can be challenging, especially with limited biopsy specimens. Recently, the driver genetic alterations underlying these neoplasms have been discovered, and their protein products can be targeted for diagnosis and therapy. Herein, we summarize the recent advances in our understanding of bone matrix-forming tumors and emphasize the integration of molecular genetics into their conventional clinicopathologic evaluation.
GSC Biological and Pharmaceutical Sciences · 2025 · 0 citations · open access
Targeting bone cancer: Emerging therapies and treatment strategies
AbstractBone cancer is a serious medical condition that affects millions of people worldwide. It is characterized by the uncontrolled growth of abnormal cells in the bone tissue, leading to tumors that can cause pain, swelling, and limited mobility. Despite advances in treatment, bone cancer remains a challenging disease to manage, with a high risk of recurrence and metastasis. This review aims to provide an overview of the current understanding of bone cancer, its types, causes, symptoms, diagnosis, and treatment options. Here also discuss the challenges and limitations of current treatments and explore potential future directions for improving patient outcomes.
Zenodo (CERN European Organization for Nuclear Research) · 2025 · 0 citations · open access
Targeting bone cancer: Emerging therapies and treatment strategies
AbstractBone cancer is a serious medical condition that affects millions of people worldwide. It is characterized by the uncontrolled growth of abnormal cells in the bone tissue, leading to tumors that can cause pain, swelling, and limited mobility. Despite advances in treatment, bone cancer remains a challenging disease to manage, with a high risk of recurrence and metastasis. This review aims to provide an overview of the current understanding of bone cancer, its types, causes, symptoms, diagnosis, and treatment options. Here also discuss the challenges and limitations of current treatments and explore potential future directions for improving patient outcomes.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works using Disease Ontology synonyms, resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
